Resource > Posters >
A human liver microphysiological system for assessing mechanisms of toxicity during drug development
Understand the advantages of using OOC to derive human translatable mechanistic insights ahead of more costly drug development phases.
Filed under: DILI and Safety toxicology
Apply the PhysioMimix DILI assay for assessing mechanisms of toxicity that cannot be typically observed using standard in vitro models.
Our approach demonstrates the ability of the assay to better inform decisions to modify drug design, aid clinical translatability and de-risk the clinical progression of drug candidates by providing detailed mechanistic understanding of toxicity.
Furthermore, the all-in-one DILI assay kit: Human 24 now allows easy access to the PhysioMimix DILI assay through provision of pre-validated cells, Liver-12 plates, specified and optimized media, plus SOP. Together, this approach enables more efficient and confident drug development and safer medicines for the future.
On-demand webinar
Go/No-Go: Gaining mechanistic insights of toxicity using a human DILI MPS to inform decision making
Watch Dr. Ovidiu Novac in our webinar to find out how you can extract mechanistic information to better guide decision making. Watch here